Histone H3 Mutation Antibody Panel (K4M, K9M, K27M, K36M) + H3.3 Mutation... Reference: REV-31-1327-MP Histone H3 is one of the DNA-binding proteins found in the chromatin of all eukaryotic cells. H3 along with four core histone proteins binds to DNA forming the structure of the nucleosome. Histones play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. Histone H3 has three main variants, H3.1 and H3.2, which are deposited in chromatin only during DNA replication and H3.3, which is replication independent and is found primarily in the regions of active transcription and heterochromatin. Post translationally, histones are modified in a variety of ways to either directly change the chromatin structure or allow for the binding of specific transcription factors. The N-terminal tail of histone H3 protrudes from the globular nucleosome core and can undergo several different types of post-translational modification that influence cellular processes. These modifications include the covalent attachment of methyl or acetyl groups to lysine and arginine amino acids and the phosphorylation of serine or threonine. Histone modifications are one form of epigenetic information that relate closely to gene regulation. Aberrant histone methylation caused by alteration in chromatin-modifying enzymes has long been implicated in cancers. Recently, recurrent histone mutations have been identified in multiple cancers and have been shown to impede histone methylation. All identified histone mutations (including H3K4M, H3K9M, H3K27M, H3K36M, and H3G34V/R/W) result in amino acid substitution at/near a lysine residue that is a target of methylation.
Efmarodocokin alfa Reference: HY-P99919 Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia.
CTX-2026 Reference: HY-P99179 CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer.
Tibulizumab Reference: HY-P99563 Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research.
Suvratoxumab Reference: HY-P99583 Suvratoxumab (MEDI4893) is a long-acting, high-affinity humanized anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394).
Spesolimab Reference: HY-P99396 Spesolimab (BI 655130) is an anti-IL-36R antibody. IL-36 involves in immune system, as Spesolimab can be used for palmoplantar pustulosis (PPP) research. Spesolimab is associated with the reduction of biomarkers linked to innate, Th1/Th17, and neutrophilic pathways.
Pimivalimab Reference: HY-P99887 Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor.
Valziflocept Reference: HY-P99529 Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE).
Berlimatoxumab Reference: HY-P99472 Berlimatoxumab (ASN-2) is an antibody. Berlimatoxumab can be used for experiment research.
Vedolizumab Reference: HY-P9911 Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
Tilvestamab Reference: HY-P99161 Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas.
Albinterferon alfa-2B Reference: HY-P99427 Albinterferon alfa-2B (alb-IFN) is a recombinant protein consisting of interferon alfa-2b genetically fused to human albumin. Albinterferon alfa-2B can be used for the research of chronic hepatitis C.